Neurocrine Biosciences | NBIX - Interest Expense On Debt


Neurocrine Biosciences reported $1.1M in Interest Expense on Debt for its fiscal quarter ending in March of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
ALKERMES USD 25.92M 5.03M Jun/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
Amgen USD 95.64B 94.98B Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 63.29M 48.34M Jun/2026
Cytokinetics USD 34.83M 1.5M Jun/2026
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 269M 22M Sep/2026
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Incyte USD 605K 23K Sep/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 667M 4M Jun/2026
Prothena USD 302.58M 47.32M Jun/2026
Regeneron Pharmaceuticals USD 11M 1.9M Jun/2026
Repligen USD 5.71M 49K Sep/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Teva Pharmaceutical Industries USD 195M 21M Jun/2026
Ultragenyx Pharmaceutical USD 22M 1000K Jun/2026
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025